A retrospective, observational study assessing CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine
Latest Information Update: 24 Jan 2020
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
Most Recent Events
- 24 Jan 2020 New trial record